Juliette Raffort1,2, Patricia Panaïa-Ferrari1,3, Fabien Lareyre2,4, Pascale Bayer1,3, Pascal Staccini3, Patrick Fénichel3,5, Giulia Chinetti6,7. 1. Clinical Chemistry Laboratory, University Hospital of Nice, 30 Avenue de la Voie Romaine CS 51069, 06002, Nice Cedex 1, France. 2. Université Côte d'Azur, CHU, CNRS, Inserm, IRCAN, Nice, France. 3. Université Côte d'Azur, CHU, Nice, France. 4. Department of Vascular Surgery, University Hospital of Nice, Nice, France. 5. Department of Endocrinology, University Hospital of Nice, Nice, France. 6. Clinical Chemistry Laboratory, University Hospital of Nice, 30 Avenue de la Voie Romaine CS 51069, 06002, Nice Cedex 1, France. giulia.chinetti@unice.fr. 7. Université Côte d'Azur, CHU, CNRS, Inserm, IRCAN, Nice, France. giulia.chinetti@unice.fr.
Abstract
INTRODUCTION: Bariatric surgery including the Roux-en-Y gastric bypass (RYGB) and the laparoscopic sleeve gastrectomy (LSG) is a well-established therapeutic option for patients with morbid or severe obesity. Metabolic modifications observed after bariatric surgery are thought to be, at least partly, linked to hormonal changes. While variation of several proglucagon-derived peptides during bariatric surgery is well documented, little is known about glicentin. The aim of this study was to investigate circulating glicentin variations after bariatric surgery. MATERIAL AND METHODS: Thirty patients eligible for bariatric surgery (18 RYGB and 12 LSG procedures) were prospectively included in the University Hospital of Nice. Clinical data and fasting biological parameters were recorded preoperatively, at 3, 6, and 12 months after bariatric surgery. RESULTS: The median age of patients was 51 years (35-56) with 33.3% men. Fasting glicentin concentration increased progressively after bariatric surgery from 6 months and was more marked at 12 months (14 ± 3.6 pmol/L at baseline vs 19.7 ± 2.7 pmol/L at 12 months for RYGB and 12.5 ± 1.4 vs 16.4 ± 1.8 pmol/L for LSG, respectively). Compared to preoperative values, the fold increase of glicentin at 12 months was 2 ± 0.2 in the RYGB group and 1.6 ± 0.3 in the LSG group. Glicentin variation after surgery did not correlate with anthropometric, glycemic, or lipid parameter modifications. CONCLUSION: Fasting glicentin level increases after bariatric surgery suggesting the potential interest of this peptide as a player and/or a marker of physiological changes after bariatric surgery.
INTRODUCTION: Bariatric surgery including the Roux-en-Y gastric bypass (RYGB) and the laparoscopic sleeve gastrectomy (LSG) is a well-established therapeutic option for patients with morbid or severe obesity. Metabolic modifications observed after bariatric surgery are thought to be, at least partly, linked to hormonal changes. While variation of several proglucagon-derived peptides during bariatric surgery is well documented, little is known about glicentin. The aim of this study was to investigate circulating glicentin variations after bariatric surgery. MATERIAL AND METHODS: Thirty patients eligible for bariatric surgery (18 RYGB and 12 LSG procedures) were prospectively included in the University Hospital of Nice. Clinical data and fasting biological parameters were recorded preoperatively, at 3, 6, and 12 months after bariatric surgery. RESULTS: The median age of patients was 51 years (35-56) with 33.3% men. Fasting glicentin concentration increased progressively after bariatric surgery from 6 months and was more marked at 12 months (14 ± 3.6 pmol/L at baseline vs 19.7 ± 2.7 pmol/L at 12 months for RYGB and 12.5 ± 1.4 vs 16.4 ± 1.8 pmol/L for LSG, respectively). Compared to preoperative values, the fold increase of glicentin at 12 months was 2 ± 0.2 in the RYGB group and 1.6 ± 0.3 in the LSG group. Glicentin variation after surgery did not correlate with anthropometric, glycemic, or lipid parameter modifications. CONCLUSION: Fasting glicentin level increases after bariatric surgery suggesting the potential interest of this peptide as a player and/or a marker of physiological changes after bariatric surgery.
Authors: C Dirksen; N B Jørgensen; K N Bojsen-Møller; S H Jacobsen; D L Hansen; D Worm; J J Holst; S Madsbad Journal: Diabetologia Date: 2012-04-27 Impact factor: 10.122
Authors: Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: Michael D Jensen; Donna H Ryan; Caroline M Apovian; Jamy D Ard; Anthony G Comuzzie; Karen A Donato; Frank B Hu; Van S Hubbard; John M Jakicic; Robert F Kushner; Catherine M Loria; Barbara E Millen; Cathy A Nonas; F Xavier Pi-Sunyer; June Stevens; Victor J Stevens; Thomas A Wadden; Bruce M Wolfe; Susan Z Yanovski; Harmon S Jordan; Karima A Kendall; Linda J Lux; Roycelynn Mentor-Marcel; Laura C Morgan; Michael G Trisolini; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Nicolai A Rhee; Camilla D Wahlgren; Jens Pedersen; Brynjulf Mortensen; Ebbe Langholz; Erik P Wandall; Steffen U Friis; Peter Vilmann; Sarah J Paulsen; Viggo B Kristiansen; Jacob Jelsing; Louise S Dalbøge; Steen S Poulsen; Jens J Holst; Tina Vilsbøll; Filip K Knop Journal: Diabetologia Date: 2015-07-18 Impact factor: 10.122
Authors: Robert Wagner; Sabine S Eckstein; Louise Fritsche; Katsiaryna Prystupa; Sebastian Hörber; Hans-Ulrich Häring; Andreas L Birkenfeld; Andreas Peter; Andreas Fritsche; Martin Heni Journal: Front Endocrinol (Lausanne) Date: 2022-06-29 Impact factor: 6.055
Authors: Fabiano Duarte Aznar; Fabio D Aznar; José R Lauris; Elinton Adami Chaim; Everton Cazzo; Silvia Helena de Carvalho Sales-Peres Journal: Arq Bras Cir Dig Date: 2019-12-09